A Phase 2 interventional study of Cyclophosphamide in Haploidentical Hematopoietic Stem Cell Transplant and Hematological Malignancies, sponsored by Tata Memorial Centre. Recruiting at 2 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Tata Memorial Centre · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing cyclophosphamide in Hematologic Neoplasms — 18 open to participants now, 20 under way, 1 of them phase 3. Cyclophosphamide · Hematologic Neoplasms.
Among the 53 studies testing cyclophosphamide in Hematologic Neoplasms, this one is the 38th largest by planned enrollment of the 52 interventional ones that give a count, is the only one that started in 2025, is one of 30 in phase 2, reaches primary completion later than 11 of the 19 other live ones, and was the 52nd registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →18 of the 53 studies testing cyclophosphamide in Hematologic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Chinese PLA General Hospital · Sites in China
Ages 18–75
Milton S. Hershey Medical Center · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 40 · Phase 3 3
First in 1998; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 44 across the 52 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 53 has an industry lead sponsor. The 10 most frequent:
Tata Memorial Centre is the lead sponsor of 64 studies on the registry; 42 are open to participants now.
Tata Memorial Centre has 5 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing cyclophosphamide in Hematologic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04959175National Cancer Institute (NCI)Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | 2027-04-27 |
| NCT05436418National Cancer Institute (NCI)The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation | 2027-06-25 |
| NCT05849207Ronald PaquettePost-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant | 2027-07-01 |
| NCT05735717Masonic Cancer Center, University of MinnesotaMT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies testing cyclophosphamide in Hematologic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant. The standard dose of this medicine is 50 mg per kg of the patient's weight given on the 3rd and the 4th day. However, using this medicine at this dose of 50 mg / kg for 2 days is associated with certain problems such as susceptibility to infections and delay in the recovery of the immune system after stem cell transplant. Therefore, several research groups across the world have tried to reduce the dose of cyclophosphamide that is used. These groups have tried reducing the dose from 50 mg per kg to 25-40 mg per kg. These studies have shown that the reduced dose cyclophosphamide is equally effective in preventing GVHD. However, these studies are carried out on small numbers of patients and further studies are essential to confirm whether reduced dose of cyclophosphamide is equally effective. In this study, we will use cyclophosphamide at a lower dose (25 mg/kg x 2 days) and see if the lower dose results in equal efficacy but lesser toxicities This is a single-arm study. All participants will receive the same treatment; there is no comparison group.
Participants will:
Adults (age ≥18) undergoing haploidentical stem cell transplant for blood cancers Receive low-dose cyclophosphamide (25 mg/kg/day) on Day 3 and Day 4 after transplant Also receive standard GVHD preventive medicines (calcineurin inhibitor and mycophenolate) Undergo regular blood tests, immune system monitoring, and GVHD assessments Have immune cell and cytokine profiles analyzed through blood samples
Background: Allogeneic Hematopoietic stem cell transplant (HSCT) is often the only curative treatment option for patients with end stage hematological malignancies. Haploidentical HSCT is increasingly being adopted worldwide due to ease of access to donors. Post transplant cyclophosphamide (PTCy) has revolutionized the way the world does T cell replete haploidentical transplant. However, the success of PTCy comes at the cost of delayed engraftment and increased organ toxicities. Reduced dose of PTCy may be equally effective in GvHD prevention and translate into better engraftment kinetics and immune reconstitution Objectives: To evaluate the GvHD prophylactic effect of reduced dose PTCy in combination with Calcineurin inhibitors and MMF for haploidentical HSCT.
Novelty: The proposed study is a prospective phase 2 trial of reduced dose PTCy as GvHD prophylaxis in haplo HSCT. By demonstration of equal GvHD prevention efficacy of reduced dose PTCy this study would provide the base for phase 3 randomised trial and provide practice changing answers.
Study treatment:
Post-transplant Immunosuppression:
● GvHD prophylaxis regimen will consist of two doses of cyclophosphamide on D+3 and D+4 at 25mg/kg/day (that is half of the usual standard dose) with calcineurin inhibitor and mycophenolate mofetil / mycophenolate sodium. Mesna will be given with cyclophosphamide (this is standard of care). The use of calcineurin inhibitors and mycophenolate mofetil / mycophenolate sodium will be as per standard practice.
Administration of study treatments
Characterization of immune cell profile using 16-color flow cytometry Peripheral blood samples will be studied for various immune cell subsets using the bulk-lyse and stain method. Antibody staining will be performed using a 16-color antibody panel and cells will be acquired on a BD LSR Fortessa flow cytometer. A minimum of 100000 cells will be studied in each panel. This panel will provide more than 100 immune cell subsets. Flow cytometry data will be analyzed using Kaluza software version 2.0 and tSNE software. The different immune cell subsets will be categorized. Absolute counts of these subsets will be calculated in PB samples with WBC counts using the dual-platform method.
Cytokine profile analysis Cytokine profile analysis for cytokines such as IL-1β, IL-6, IL-8, IL-10, IL-12p70, IFN-γ, TNF-α, IP-10, GM-CSF, etc., will be performed using the patient's peripheral blood plasma samples (within 4 h of collection) using a bead-based immunoassay (CBA, BD Biosciences, and BioLegend's LEGENDplex™) according to the manufacturer's instructions. In brief, 50 µL of prepared capture bead mixture will be mixed with 50 µL of the diluted sample and incubated at room temperature for 1.5 h. Then, 50 µL of the detection reagent will be added to this mixture and incubated for 1.5 h. The detection reagent is a mixture of analyte-specific antibodies conjugated to phycoerythrin. Incubation of the samples with capture beads and then the detection reagent leads to the formation of a "sandwich complex" of the three. These complexes will be acquired on LSRFortessa (BD Biosciences), and data will be analyzed using FCAP Array software (BD Biosciences) and LEGENDplex version 8.0 software (BioLegend).
Sample size Based on our historical data, the expected incidence of grades 3 and 4 aGvHD is estimated to be 30%. The study will enroll a total of 20 patients using a Simon 2-stage design. If in the initial 10 patients enrolled, 4 or more develop acute grade III or IV GVHD, then we will stop the study. If 3 or less patients develop acute grade III or IV GVHD, then we will complete the enrollment of the planned 20 patients. We expect to complete the enrollment in 4 years.
Statistical Analysis All continuous data will be expressed as median and IQR. Categorical data will be expressed as frequency and percentage. The incidence of acute and chronic GvHD, relapse, and NRM will be estimated based on cumulative incidence methods accounting for competing event (TRM or death due to any cause). Overall Survival and Relapse Free Survival probabilities will be estimated by the Kaplan-Meier method.
The platelet and neutrophil engraftment will be expressed using median and IQR. Statistical analysis will be performed by appropriate statistical tests using IBM SPSS v25 (statistical package for social sciences) software.
Study Timeline and Oversight
Duration: 4 years (estimated)
Site: Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
Sample size: 20 patients
Provision of ancillary care for unrelated illness during the duration of the study:
Allogeneic stem cell transplant is associated with development of several kinds of post-transplant complications. All such complications will be managed as per standard of care by the transplant team and as mentioned previously, the patient will bear the cost of such management.
Plan for Missing Data Predefined rules will be applied to classify missing, uninterpretable, or inconsistent data.
Privacy, confidentiality and anticipated consequences of breach of confidentiality:
All the study data will remain in a password protected document which will be accessible only to the study investigators and the regulatory authorities. In any presentation originating from the study or any publication, no reference will be made to individual patients. Any data presentation will always be de-identified.
The fact that the patient has undergone an allogeneic HSCT would be available / made known to several clinicians and other medical / paramedical staff who would be involved in patient care. Since there are no additional study specific assessments or follow ups, any breach of information about your trial participation is unlikely to have any consequences.
Compensation and reimbursement:
Transplant related complications (which may lead to fatal outcomes) are inherent complications of half-matched transplants. These could occur irrespective of trial participation. Therefore, the study does not have a provision for compensation (since these complications can occur irrespective of study participation). Also, because of the same reason, there is no reimbursement and the cost of management of complications will be borne by the patient.
All trial-related data will be collected in accordance with institutional standard operating procedures (SOPs).
Inclusion Criteria: -
Exclusion Criteria: -
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Arm study and cyclophosphamide at a lower dose (25 mg/kg x 2 days)
Drug: Cyclophosphamide
Post-transplant Immunosuppression: ● GvHD prophylaxis regimen will consist of two doses of cyclophosphamide on D+3 and D+4 at 25mg/kg/day (that is half of the usual standard dose) with calcineurin inhibitor and mycophenolate mofetil / mycophenolate sodium. Mesna will be given with cyclophosphamide (this is standard of care). The use of calcineurin inhibitors and mycophenolate mofetil / mycophenolate sodium will be as per standard practice. Administration of study treatments * Hydration and MESNA * Adequate intravenous hydration with normal saline will be started at least 4 hours prior to cyclophosphamide, and will be continued till 24 hours post completion of 2nd dose of cyclophosphamide as per standard institutional practice. * Mesna will be administered as a continuous infusion starting from Day+3 till 24 hours after the second dose of PTCy. * Cyclophosphamide * Cyclophosphamide would be administered on D+3 and D+4 \[first dose starting between 60 - 72 hrs after stem cell infusion\]
Severe (Grade 3-4) aGvHD
To evaluate the cumulative incidence of severe (Grade 3-4) aGvHD
Time frame: at day 100 Post Transplant
Cumulative incidence of clinically significant (Grade 2-4) acute graft-versus-host disease (aGvHD)
To evaluate the cumulative incidence of clinically significant (Grade 2-4) acute GvHD following transplantation.
Time frame: Day 100 and Day 180 post-transplant
Cumulative incidence of severe (Grade 3-4) acute graft-versus-host disease (aGvHD)
To evaluate the cumulative incidence of severe (Grade 3-4) acute GvHD following transplantation.
Time frame: Day 180 post-transplant
Graft-versus-host disease and relapse-free survival (GRFS)
To evaluate graft-versus-host disease and relapse-free survival (GRFS). GRFS events include grade III or IV acute GvHD, extensive chronic GvHD, disease relapse, or death.
Time frame: 1 year post-transplant
Incidence of chronic graft-versus-host disease (cGvHD
To evaluate the cumulative incidence of chronic GvHD following transplantation.
Time frame: 1 year post-transplant
Neutrophil engraftment
To evaluate the time to neutrophil engraftment following transplantation, defined according to the study protocol.
Time frame: Up to Day 100 post-transplant
Platelet engraftment
To evaluate the time to platelet engraftment following transplantation, defined according to the study protocol.
Time frame: Up to Day 100 post-transplant
Regimen-related toxicity
To evaluate the incidence and severity of regimen-related toxicity following transplantation.
Time frame: Up to Day 100 post-transplant
Transplant-related mortality (TRM)
To evaluate the cumulative incidence of transplant-related mortality following transplantation.
Time frame: 1 year post-transplant
Overall survival (OS)
To evaluate overall survival following transplantation.
Time frame: 1 year post-transplant
Plan to share: No — At this time, we do not plan to share individual participant data (IPD) due to concerns regarding patient privacy, the regulatory requirements for data sharing for maintaining patient confidentiality
Started Mar 2025 (actual). Primary completion is estimated for Nov 2028, 43 months after the start.
Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's planned 43 months is below that.
Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclophosphamide
Tata Memorial Centre